MedTrace Logo

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT06599229 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

DIAGNOSTIC_TEST

myocardial contrast echo

Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2026-05-30
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06599229 on ClinicalTrials.gov